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Non-adherence to antipsychotic medication is common and increases the risk of psychotic relapse. A promising intervention may be a strategy wherein financial incentives are offered. 

Methods
In a pilot study in The Netherlands, five patients with schizophrenia were offered financial incentives for a duration of one year to improve adherence to medication. Adherence and hospital days were measured. 

Results
The percentage of accepted depot injections increased from an average of 44% in the previous year to 100% in the year when financial incentives were offered. While patients had been hospitalised for an average of 100.2 days in the previous year, only one was re-admitted for 17 days during the year of the intervention. 

Conclusions







Non-adherence to antipsychotic medication in schizophrenia is high (1, 2) and is associated with a three to five times increased risk of relapse (3, 4, 5). Developing effective interventions for improving adherence is a major challenge to mental health care. In the UK, Claassen et al. (6) used financial incentives to improve the adherence to antipsychotic maintenance medication in five formerly non-adherent patients. Results were promising, yet no other studies have since been published. 






Patients were gathered in Rotterdam, The Netherlands. Written informed consent was obtained from all patients after providing them with a complete description of the study. The intervention was over a one year period and the study was conducted from July 2008 to October 2009. A Medical Ethics Committee (METIGG, The Netherlands) approved the study (ref-number: 8208; CCMO number: NL22014.097.08). 

Intervention: financial incentives for adherence
Patients received ten to twenty Euro cash (fifteen to thirty US $) for each depot injection of antipsychotic medication. The amount of money depended on the frequency of the depot. Ten Euro were offered for a depot administered every two weeks, 15 Euro for a depot every weeks, and 20 Euro for a depot every four weeks. 

Respondents
Inclusion criteria were (1) a diagnosis of schizophrenia or schizoaffective disorder, (2) being treated in the act-team for a period of one year or more, (3) the prescription of depot antipsychotic medication, (4), non-adherence, as defined by either not accepting all depot injections or repeated resistance and discussion when accepting the medication, (5) having been admitted to a psychiatric hospital in the past year as a consequence of non-adherence (as assessed by the responsible clinician). 
Six patients were asked to participate out of which one refused and five decided to participate. Two patients were native to The Netherlands. The others were first-generation immigrants; one from Suriname, one from Turkey, and one from the Dutch Antilles. For more details, see Table 1. 

Measurements





Depot acceptance and hospital days
As Table 1 shows, all five patients accepted every depot injection of antipsychotic medication during the year of the intervention. During the year before the intervention, adherence was much lower. Patient B had previously always declined a depot injection of antipsychotics, despite the fact that mental health professionals had often tried to motivate him because of his poor compliance with oral medication and his recurring and severe psychotic relapses. 
	The number of days patients spent in psychiatric in-patient care decreased during the intervention. Only one of the five patients was admitted whilst being offered financial incentives. However, the same patient (B), during the period of the intervention, had been in detention for 195 days for domestic violence while being in a psychotic state. Thus, the incentives improved adherence, but the medication did not sufficiently control his psychotic symptoms. 

-- insert Table 1 somewhere here --

Views of patients, relatives and clinicians 
In the short questionnaire on the experiences with the intervention all five patients considered the intervention to be a good project. The reasons they gave were “I don’t like the injection, but money makes it better,” “Money keeps me motivated,” and “The depot injections keep me balanced.” When prompted, two patients said that they perceived financial incentives as a voluntary and non-coercive measure, two patients did not know what to think about this, and one indicated that he perceived financial incentives as a coercive measure, saying that “I have to take the medication anyway.” All patients said that they spent the money on food and on cigarettes, and one patient also bought household products. It was observed, however, that at least one patient had spent some of the money on cannabis. All five patients stated that the amount of money was too low. None of them, however, had asked for more money during the intervention. All five patients said that they preferred receiving cash to other systems of reward such as vouchers for food, sports activities, etc. 
Three patients either had no relatives or did not allow us to interview them in this study. The two interviewed relatives – two mothers – indicated that they considered financial incentives to be a good measure, saying that “There can never be enough research” and “This project is in the best interest of both the patient and his parents.” They considered the amount of money to be sufficient, and they preferred the reward of money over vouchers. 

During the intervention, two patients had repeatedly asked for their depot injections sooner than scheduled, which was always declined. Despite this, no clinician reported a negative impact on the therapeutic relationship. Two patients complained about side-effects, and one expressed concerns that the depot injection could kill him, after watching a TV program in which someone died as a result of medication. 





The pilot results are promising and seem to indicate that offering financial incentives can increase adherence with depot antipsychotics and, as a consequence, reduce the risk of relapse in patients with schizophrenia that are treated in an ACT-team. The difference in adherence and clinical outcomes with the total prevention of further hospitalisations in four out of five patients is substantial. The benefits of such changes for the patients concerned and their relatives as well as the reduction of service costs appear to justify the intervention. 
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Table 1		Hospital days and depot acceptance both before and during the intervention

		One year before the intervention	One year during the intervention
Patient (sex; age)	DSM-IV diagnosis	Hospital days	Depots accepted*	Hospital days	Depots accepted*
A (male; 23 yrs)	Schizophrenia, paranoid subtype	76	45%	0	100%
B (male; 24 yrs)	Schizophrenia, paranoid subtype	260	0%	17	100%
C (male; 21 yrs)	Schizophrenia, paranoid subtype	89	20%	0	100%
D (male; 43 yrs)	Schizophrenia, paranoid subtype	14	100%	0	100%
E (male; 34 yrs)	Schizophrenia, disorganised subtype	62	55%	0	100%
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